Session » Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782)

Date: Sunday, October 26, 2025

Time: 1:00PM-2:30PM

Meeting: ACR Convergence 2025

1:00PM-1:15PM: Abstract Number: 0777

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

1:15PM-1:30PM: Abstract Number: 0778

Clinical significance of non-infectious increased procalcitonin in Still’s disease: A predictor of macrophage activation syndrome

1:30PM-1:45PM: Abstract Number: 0779

Interim Results of a Randomized Placebo Controlled Study of IL-1 Inhibitor Goflikicept in Patients With Familial Mediterranean Fever

1:45PM-2:00PM: Abstract Number: 0780

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

2:00PM-2:15PM: Abstract Number: 0781

Comprehensive mass cytometry analyses of disease-related cells in adult-onset Still’s disease

2:15PM-2:30PM: Abstract Number: 0782

Expansion of T-bet⁺ Age-Associated B Cells Is Associated with Clinical Complications in Still’s Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].